Nanobiotix shares at the bottom of the SBF 120, down 12% over the week
The Paris-based oncology nanomedicine biotech is catching its breath after a sharp rebound, in a Paris market trending lower. The decline coincides with the first of the management's two presentations in London to the financial community.
A steeper decline than the index, below the moving averages
The Nanobiotix share fell 4.33% to €25.18 in mid-morning trading, while the SBF 120 dropped 1.04%.
The stock is among the largest decliners in the index, in a market weighed down by the correction in artificial intelligence-related stocks, which hit Wall Street on Monday and Asia this morning. It is down nearly 12% over the week, but retains a gain of about 32% over one month. The October rebound had brought it back toward its moving averages, and today's session pushes it back below the MA20 (€27.51) and the MA50 (€26.44), which the price had regained in early November.
The MA200 stands at €29.82, 15.6% above the current price. The RSI at 44 remains neutral: there is no selling excess, just a pullback after several sessions of gains.
Two meetings in London with the financial community on November 16 and 17
The press release of November 9 sets the dates on which management will speak to investors: the Jefferies conference on November 16 and the UBS conference on November 17. These presentations are part of the company's financial calendar and do not constitute a new strategic announcement.
On the fundamentals, the first-half 2026 results, published on September 24, showed cash of €110.9 million, enough to fund operations until 2029according to the company. The stock has support at €18.85 and resistance at €30.36, a level the share had broken above at the end of October.
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
SectorPharmacie et biotechnologies›Biotechnologies
Context
Period
Period: S1 2026
Key reported figures
Revenue: 3,6 millions d'euros
Quarterly revenue: 3,6 millions d'euros
Net income: -34,3 millions d'euros
Guidance from the release
« la Société estime qu'elle disposera des liquidités suffisantes pour faire face à ses obligations financières […] pendant au moins les 12 prochains mois […] pas de doute substantiel quant à la capacité de la Société à poursuivre son activité » ; CP du 24/09 : trésorerie de 110,9 M€ « permettront de financer ses opérations jusqu'en 2029 »
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.